Intellia Therapeutics, Inc. (NTLA) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Intellia Therapeutics’s revenue went from $16M in fiscal 2016 to $68M in fiscal 2025, growth of about 17.0% a year.
Net income in fiscal 2025 was -$413M, a net margin of -609.9%; the best year in this period was 2016 with -$32M.
Over the twelve months to September 30, 2026, revenue was $53M and net income -$426M.
Free cash flow was -$396M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 487597% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53M | $68M | $58M | $36M | $52M | $33M | $58M | $43M | $30M | $26M | $16M |
| Gross profit | — | — | — | — | — | $33M | $58M | $43M | $30M | — | — |
| Operating income | -$434M | -$441M | -$534M | -$515M | -$458M | -$268M | -$137M | -$106M | -$91M | -$70M | -$32M |
| Net income | -$426M | -$413M | -$519M | -$481M | -$474M | -$268M | -$134M | -$474M | -$85M | -$68M | -$32M |
| EPS (diluted) | $-3.34 | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | $-2.11 | $-1980.00 | $-1880.00 | $-1420.00 |
| R&D | $335M | $389M | $466M | $435M | $420M | $230M | $150M | $108M | $89M | $68M | $32M |
| Revenue growth | — | +16.9% | +59.6% | −30.4% | +57.7% | −43.0% | +34.5% | +41.6% | +16.5% | +58.5% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$355M | -$395M | -$349M | -$394M | -$333M | -$225M | -$50M | -$103M | -$61M | -$65M | $36M |
| Capital spending | -$3M | -$1M | -$6M | -$14M | -$14M | -$13M | -$4M | -$7M | -$6M | -$10M | -$6M |
| Free cash flow | -$358M | -$396M | -$355M | -$408M | -$347M | -$238M | -$53M | -$110M | -$68M | -$75M | $30M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $63M | $80M | $154M | $134M | $91M | $47M | $20M | $15M | $17M | $15M | $7M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $450M | $602M | $912M | $1.2B | $749M | $597M | $280M | $314M | $341M | $273M |
| Debt | — | $93M | $210M | $115M | $131M | $74M | $39M | $18M | $0 | $0 | $0 |
| Equity | — | $671M | $872M | $1.1B | $1.2B | $1.0B | $527M | $270M | $278M | $301M | $210M |
| Total assets | — | $842M | $1.2B | $1.3B | $1.5B | $1.3B | $676M | $334M | $347M | $376M | $299M |
| Shares (diluted) | 140M | 108M | 99M | 89M | 77M | 71M | 56M | 0M | 0M | 0M | 0M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating margin | -821.2% | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% | -235.5% | -246.8% | -298.6% | -266.3% | -195.2% |
| Net margin | -805.7% | -609.8% | -896.8% | -1326.5% | -909.8% | -810.5% | -231.5% | -1100.1% | -280.4% | -258.6% | -192.0% |
| FCF margin | -677.1% | -585.0% | -612.8% | -1124.9% | -665.5% | -719.4% | -92.2% | -255.3% | -222.2% | -288.6% | 181.7% |
| ROIC | — | -45.6% | -39.0% | -34.9% | -26.5% | -19.0% | -19.1% | -29.1% | -25.8% | -18.3% | -15.3% |
| ROE | — | -61.5% | -59.5% | -45.8% | -38.4% | -25.8% | -25.5% | -175.7% | -30.7% | -22.5% | -15.1% |
Frequently asked questions
What is Intellia Therapeutics’s annual revenue?
$68M in fiscal 2025 and $53M over the twelve months to September 30, 2026.
How much profit does Intellia Therapeutics make?
Net income was -$413M in fiscal 2025 (net margin -609.9%).
Is Intellia Therapeutics’s revenue growing?
Yes: revenue rose 16.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.